Alphatec Holdings, Inc. (NASDAQ:ATEC) Given Consensus Rating of "Buy" by Analysts

Key Points

• Alphatec Holdings, Inc. has received an average consensus rating of "Buy" from six analysts, with an average 1-year price target of $18.50.
• The company recently reported earnings of $0.02 EPS, surpassing analysts' expectations, with a 27.5% revenue increase compared to the same quarter last year.
• Insider transactions have seen CEO Patrick Miles sell 300,000 shares for approximately $4.7 million, indicating a notable decrease in his ownership stake.

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) have earned an average rating of "Buy" from the six ratings firms that are covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $18.50.

A number of equities analysts have commented on the stock. Lake Street Capital raised shares of Alphatec to a "buy" rating and set a $18.00 price target for the company in a research note on Monday, June 16th. Barclays reissued an "overweight" rating and issued a $22.00 price target (up previously from $21.00) on shares of Alphatec in a research note on Monday, August 4th. Canaccord Genuity Group reissued a "buy" rating and issued a $20.00 price target on shares of Alphatec in a research note on Friday, August 1st. Finally, Wall Street Zen cut shares of Alphatec from a "buy" rating to a "hold" rating in a research note on Friday.

Alphatec Stock Performance

NASDAQ ATEC opened at $14.75 on Tuesday. The company's 50 day moving average is $14.78 and its 200-day moving average is $12.44. The firm has a market cap of $2.18 billion, a P/E ratio of -13.05 and a beta of 1.02. Alphatec has a 12-month low of $4.88 and a 12-month high of $16.70. The company has a quick ratio of 1.77, a current ratio of 2.88 and a debt-to-equity ratio of 23.22.

Alphatec (NASDAQ:ATEC - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The medical technology company reported $0.02 EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.08. Alphatec had a negative net margin of 24.33% and a negative return on equity of 1,657.19%. The business had revenue of $185.54 million during the quarter, compared to analysts' expectations of $178.85 million. During the same quarter in the previous year, the company earned ($0.29) EPS. The business's quarterly revenue was up 27.5% compared to the same quarter last year. Alphatec has set its FY 2025 guidance at EPS. Sell-side analysts predict that Alphatec will post -1.08 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Patrick Miles sold 300,000 shares of the company's stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $15.73, for a total value of $4,719,000.00. Following the completion of the sale, the chief executive officer owned 5,564,078 shares of the company's stock, valued at approximately $87,522,946.94. This represents a 5.12% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP David Sponsel sold 2,555 shares of the company's stock in a transaction on Friday, September 19th. The shares were sold at an average price of $15.34, for a total transaction of $39,193.70. Following the completion of the sale, the executive vice president directly owned 531,861 shares of the company's stock, valued at $8,158,747.74. This trade represents a 0.48% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 686,057 shares of company stock worth $10,439,311 in the last ninety days. 20.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Alphatec

Several institutional investors have recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. boosted its position in Alphatec by 8.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 11,845 shares of the medical technology company's stock valued at $131,000 after buying an additional 955 shares during the period. Nisa Investment Advisors LLC boosted its position in Alphatec by 22.4% during the 2nd quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company's stock valued at $63,000 after buying an additional 1,045 shares during the period. Oppenheimer Asset Management Inc. boosted its position in Alphatec by 8.4% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 14,244 shares of the medical technology company's stock valued at $158,000 after buying an additional 1,100 shares during the period. ProShare Advisors LLC boosted its position in Alphatec by 5.6% during the 2nd quarter. ProShare Advisors LLC now owns 23,790 shares of the medical technology company's stock valued at $264,000 after buying an additional 1,254 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in Alphatec by 4.6% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 40,734 shares of the medical technology company's stock valued at $413,000 after buying an additional 1,792 shares during the period. Hedge funds and other institutional investors own 66.35% of the company's stock.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.